Pharmaceutical Executive Daily
New research suggests Ozempic may reduce biological age.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
FDA Approval and New Research
The FDA has approved Bayer’s Lynkuet, also known as elinzanetant, as the first dual neurokinin 1 and 3 receptor antagonist for the treatment of moderate to severe vasomotor symptoms associated with menopause.
The approval is based on Phase III OASIS trial data showing significant reductions in hot flash frequency and severity.
As a non-hormonal option, Lynkuet provides an important new therapeutic alternative for patients seeking relief from menopausal symptoms without estrogen exposure.
Other News
- New research suggesting Ozempic may reduce biological age
- Novartis’ $12 billion merger agreement to acquire Avidity Biosciences
Author's summary: New research on Ozempic and its effects.